Efficacy of fumagillin bicyclohexylamine on experimental corneal neovascularization in rat model
Tóm tắt
Fumagillin has been previously used to treat corneal microsporidial keratitis and also identified as an angiogenesis inhibitor. This study aimed to evaluate efficacy of fumagillin bicyclohexylamine on the rat model of corneal neovascularization induced by silver nitrate cauterization. Twenty-four Albino Wistar rats (n = 24) were divided into three groups. Following silver nitrate-induced corneal injury, eyes in Group 1 received one drop of 5 mg/mL topical fumagillin bicyclohexylamine four times daily for 10 days. Group 2 received subconjunctival injection of 0.1 mL fumagillin bicyclohexylamine (2.5 mg/mL) on day 1 and day 5. Group 3 received artificial tears and lubricants four times daily for 10 days as control. On day 10, animals were sacrificed. Corneal specimens were obtained and prepared to assess vascular endothelial growth factor (VEGF-C) levels and corneal angiogenic microvessel density. There was no significant difference in VEGF-C levels between the groups (P = 0.994). Assessment of angiogenic microvessel density for peripheral corneal zone also did not reveal significant difference between the groups (P = 0.113). However, mean vascular density in Group 1 and Group 2 was significantly higher for both midperipheral and central corneal zones in comparison with Group 3 (P = 0.003, P = 0.015). Previously proved to be effective for treatment of microsporidial keratitis in humans, topical and subconjunctival concentration or dosing of fumagillin bicyclohexylamine failed to reduce corneal neovascularization induced by silver nitrate in this study. Further studies comparing different concentrations and dosing may detect inhibitory effects of fumagillin on corneal neovascularization without inducing toxicity.
Tài liệu tham khảo
Joussen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V (2001) Inhibition of inflammatory corneal angiogenesis by TNP-470. Invest Ophthalmol Vis Sci 42:2510–2516
Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249
Cursiefen C, Schlotzer-Schrehardt U, Kuchle M et al (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 43:2127–2135
Cursiefen C, Chen L, Dana MR, Streilein JW (2003) Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 22:273–281
Regina M, Zimmerman R, Malik G, Gausas R (2007) Lymphangiogenesis concurrent with haemangiogenesis in the human cornea. Clin Exp Ophthalmol 35:541–544
Haynes WL, Proia AD, Klintworth GK (1989) Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 30:1588–1593
Lipman RM, Epstein RJ, Hendricks RL (1992) Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 110:405–407
Joussen AM, Kruse FE, Volcker HE, Kirchhof B (1999) Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237:920–927
Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47:3339–3344
Lepri A, Benelli U, Bernardini N et al (1994) Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 10:273–280
Xiao O, Xie ZL, Lin BW, Yin X, Pi RB, Zhou SY (2012) Minocycline inhibits alkali burn-induced corneal neovascularization in mice. PLoS ONE 7:1–9
Dan L, Shi-long Y, Miao-li L et al (2008) Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr Eye Res 33:653–660
Su W, Li Z, Lin M, Li Y, He Z et al (2011) The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats. Graef Arch Clin Exp 249:421–427
Peyman GA, Kazi AA, Riazi-Esfahani M et al (2006) The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea 25:582–585
Chen WL, Lin CT, Lin NT et al (2009) Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50:1659–1665
McCowen MC, Callender ME, Lawlis JF (1951) Fumagillin (H-3) a new antibiotic with amebicidal properties. Science 113:202–203
Killough JH, Magill GB, Smith RC (1952) The treatment of amebiasis with fumagillin. Science 115:71–72
Ketznelson H, Jamieson CA (1952) Control of Nosema disease of honey bees with fumagillin. Science 115:70
Lowder CY, McMahon JT, Meisler DM et al (1996) Microsporidial keratoconjunctivitis caused by Septata intestinalis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 121:715–717
Vemuganti GK, Garg P, Sharma S, Joseph J, Gopinathan U, Singh S (2005) Is microsporidial keratitis an emerging cause of stromal keratitis? A case series study. BMC Ophthalmol 5:19
Diesenhouse MC, Wilson LA, Corrent GF, Visvesvara GS, Grossniklaus HE, Bryan RT (1993) Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am J Ophthalmol 115:293–298
Cali A, Meisler DM, Lowder CY et al (1991) Corneal microsporidioses: characterization and identification. J Protozool 38:215–217
Ingber D, Fujita T, Kishimoto S (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557
Mahoney JM, Waterbury LD (1985) Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 4:531–535
Oh SJ, Jeltsch MM, Birkenhager R et al (1997) VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188:96–109
Skobe M, Hawighorst T, Jackson DG et al (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–198
Ling S, Lin H, Liang L et al (2009) Development of new lymphatic vessels in alkali burned corneas. Acta Ophthalmol 87:315–322
Lanternier F, Boutboul D, Menotti J et al (2009) Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 11:83–88
Molina JM, Goguel J, Sarfati C et al (2000) Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 14:1341–1348
Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, Balkan S, Derouin F, Agence Nationale de Recherches sur le SIDA 090 Study Group (2002) Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 346:1963–1969
Loh RS, Chan CM, Ti SE, Lim L, Chan KS, Tan DT (2009) Emerging prevalence of microsporidial keratitis epidemiology, clinical features and management. Ophthalmology 116:2348–2353
Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO (1998) Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 95:15183–15188
Zhang P, Nicholson DE, Bujnicki JM et al (2002) Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci 9:34–40
Kieser A, Weich HA, Brandner G, Marme D, Kolch W (1994) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963–969
Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T (2000) TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. Anticancer Res 20:601–604
Kanno T, Uehara T, Osawa M et al (2015) Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells. Biochem Biophys Res Commun 463:1267–1272
Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566–2570